Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Trump’s Proposed Budget Undermines His H.I.V. Plan, Experts Say

    Strategies abound to end the AIDS epidemic, but expense — mostly for drugs costing up to $50,000 a year — is the inevitable obstacle.

    14 March 2019 | The New York Times
  • Gilead's Descovy snared its PrEP data, but can it stand up to Truvada generics?

    Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a different story.

    14 March 2019 | FiercePharma
  • Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes

    Dozens of patient advocacy groups, like the Bonnie J. Addario Lung Cancer Foundation and the National Coalition for Cancer Survivorship, recently appeared in national advertisements objecting to a Trump administration proposal that could limit drugs covered by Medicare providers. But a Kaiser Health News analysis found that about half of the groups representing patients have received funding from the pharmaceutical industry.

    05 March 2019 | Kaiser Health News
  • Should the NIH Break HIV Prevention Drug Truvada's Patent?

    Should a biotech giant holding a valuable patent be forced to give it up if doing so would serve the public good? That’s the mounting debate over Gilead Sciences’ hold on an HIV prevention treatment, which some say is too expensive and should be available to all.

    05 March 2019 | Fortune
  • Hepatitis C Treatment Market to Exceed US$ 71.13 Bn by the end of 2024

    The global hepatitis C treatment market was valued at US$ 23.9 Bn in 2015 and is estimated to be valued at US$ 26.6 Bn by 2016. The market is expected to reach a valuation of US$ 71.13 Bn by the end of 2024, reflecting a cumulative annual growth rate of 13.1% over the forecast period.

    04 March 2019 | Honest Businessman
  • A new way to pay for innovative drugs, provide universal access and not break the bank

    Louisiana, which has a severe hepatitis C problem, is on the cusp of proving to other states that drug companies can make the money they need, while every Medicaid recipient who needs a cure gets one. The state is now on a path to secure immediate treatment for all infected prisoners and people on Medicaid by buying a license from a drug company. It is a concept that can be applied to other ground breaking remedies.

    28 February 2019 | The Conversation
  • Analysis: How a cutting edge medicine made it to South Africa’s new ARV tender

    South Africa’s recently awarded antiretroviral (ARV) tender, worth around R14-billion over three years, heralds the introduction of a much-anticipated new medicine called dolutegravir into the public healthcare system from July 2019. For a cutting-edge HIV drug to reach the public sector so quickly, and at such a low price, is unprecedented.

    27 February 2019 | Spotlight
  • The Good Law Project threatens Judicial Review of Serious Shortage Protocols

    The Good Law Project has today threatened to issue judicial review proceedings on Tuesday 26 February unless Government cancels powers to allow pharmacists to alter prescriptions for people with serious medical conditions in the event of medicines shortages. The powers – called “Serious Shortage Protocols” (SSPs) – give pharmacists the right to supply a different quantity or pharmaceutical quality of medicine in the event of the country experiencing a serious shortage of prescription-only medicines after 29 March 2019. These new powers took force on 9 February, and have been criticised for being rushed out without proper consultation with patient and clinical groups.

    24 February 2019 | Good Law Project
  • US: The struggle to maintain access to lifesaving HIV meds

    President Trump actually proposed a plan in his State of the Union address to end the HIV epidemic in America by 2030. This lofty goal would be thwarted, however, by proposed changes to Medicare Part D that jeopardize the advancements we’ve made in the fight against HIV.

    24 February 2019 | Washington Blade
  • The Trump Administration's Drug Pricing Proposals for People With HIV, Explained

    Every once in a while, we like to try to explain wonky policy proposals that haven't happened yet but that could be of significance for HIV-positive folks if they do.

    20 February 2019 | The Body
More news
Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.